Sara Graffdaugherty is a seasoned Clinical Program Manager at Gilead Sciences, where she plays a pivotal role in the oversight of biopharmaceutical drug development programs, particularly within the realms of Early Phase Development. With a robust clinical research background dating back to 2006, Sara has...
Sara Graffdaugherty is a seasoned Clinical Program Manager at Gilead Sciences, where she plays a pivotal role in the oversight of biopharmaceutical drug development programs, particularly within the realms of Early Phase Development. With a robust clinical research background dating back to 2006, Sara has honed her expertise in Program and Portfolio Management, Clinical Trial Management (CTM), Clinical Trial Agreement (CTA) negotiations, and Clinical Research Associate (CRA) management. Her extensive experience spans multi-center global studies across Phases I-IV, allowing her to navigate the complexities of clinical trials with ease.
At Gilead, Sara is deeply involved in therapeutic areas that are critical to public health, including Virology, with a focus on HIV/AIDS, COVID-19, and emerging viral threats like Ebola and MERS. Her responsibilities encompass the entire lifecycle of clinical studies, from the proposal and bid-defense stages to project start-up, execution, and close-out. This comprehensive oversight ensures that projects are not only compliant with regulatory standards but also aligned with Gilead's commitment to innovation and patient safety.
Sara's skill set is further enhanced by her proficiency in data monitoring and pharmacovigilance, which are essential for maintaining the integrity of clinical data and ensuring participant safety. Her leadership capabilities and customer relationship management skills enable her to foster strong collaborations with cross-functional teams and external stakeholders. As she continues to drive process improvements within clinical operations, Sara remains dedicated to advancing therapeutic solutions that address unmet medical needs, making her a vital asset to Gilead Sciences and the broader biopharmaceutical landscape.
